APA (7th ed.) Citation

Dennen, S., Masek, M., Cockrum, P., Nagelhout, E., & Paluri, R. Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma. Columbia Data Analytics, LLC.

Chicago Style (17th ed.) Citation

Dennen, Syvart, Marty Masek, Paul Cockrum, Elizabeth Nagelhout, and Ravi Paluri. Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma. Columbia Data Analytics, LLC.

MLA (9th ed.) Citation

Dennen, Syvart, et al. Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma. Columbia Data Analytics, LLC.